Mabylon AG Initiates Phase I Clinical Trial of Lead Compound MY006 for the Treatment of Peanut Allergy
— First study participant dosed in U.S. trial with healthy volunteers and patients with peanut allergy
— Novel, human-derived, half-life extended tri-specific monoclonal antibody to prevent allergic reactions
Mabylon AG, a leader in the high-throughput discovery, engineering, and development of human-derived antibodies for the treatment of allergies, neurodegenerative diseases, and inflammation, today announced that the first healthy volunteer has been dosed in the first-in-human clinical trial evaluating MY006, a novel tri-specific monoclonal antibody for the prophylactic treatment of peanut allergy. MY006 is based on patient-derived antibodies and designed to provide a new approach for preventing allergic reactions in individuals with peanut allergy.
tiakis Biotech Successfully Completes Data Package to Advance Tiprelestat into Phase II clinical trial in PAH
— 6-month GLP-tox study reinforces favorable safety profile of Tiprelestat
— Phase II Study in Pulmonary Arterial Hypertension (PAH) to be initiated by Stanford University in mid-2026
tiakis Biotech AG (“tiakis”), a clinical-stage biopharmaceutical company developing novel therapeutics for life-threatening pulmonary and cardiovascular diseases, today announced that the Company has successfully finalized a comprehensive data package to advance Tiprelestat into a Phase II clinical trial in Pulmonary Arterial Hypertension (PAH) by completing a preclinical GLP-tox study.
Captain T Cell Closes Financing Round to Advance its Proprietary, Next-Generation TCR-T Pipeline Into the Clinic
- Available funding totaling EUR 20 million dedicated to developing novel solid tumor treatments addressing a high unmet medical need
- Springboard Health Angels, Pluton Asset Holding AG, Sintra Limited, and Technologiegründerfonds Sachsen joined as new investors
- Existing investors i&i Biotech Fund I SCSp, HIL-INVENT and Brandenburg Kapital also participated in the round
Captain T Cell, a biotechnology company developing next-generation TCR-T cell therapies for solid tumors, today announced the successful closing of an equity financing round with both new and existing investors. The latest equity funding, along with already secured grants, provides Captain T Cell with a total budget of EUR 20 million to advance its best-in-class autologous program CTC127 to clinical Phase I read-outs and its first-in-class allogeneic program for off-the-shelf solid tumor treatments towards clinical trial readiness.
